Skip to main content

Table 1 Decreased serum CC16 levels and risk of high dose ICS requirement in asthma patients

From: Effects of obesity on CC16 and their potential role in overweight/obese asthma

Impact for a 1-SD decrease in serum CC16 levels

OR (95% CI)

p-value

Crude

1.87 (1.28, 2.73)

< 0.001

Model 1

1.88 (1.20, 2.83)

0.001

Model 2

1.75 (1.16, 2.65)

0.004

  1. Patients with current oral corticosteroid use were excluded (n = 45). The figure indicates unadjusted associations between values of serum CC16 and ICS dose. Model 1 adjusted for age, sex, smoking status, pack-year, CC16 A38G polymorphism (rs3741240). Model 2 adjusted for covariates in Model 1 and BMI
  2. Equivalent to budesonide dose was used to divide asthma patients into high (n = 82) vs non-high groups (n = 79) according to the cutoff values provided by the GINA guideline
  3. OR odds ratio, CI confidence interval
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us